Glythera specialises in the development of next generation biotherapeutics, through the application of its advanced proprietary linker and stable glycan technologies: PermaLink® and PermaCarb®. Our conjugation chemistries platforms have the potential to enhance and strengthen pharmaceutical drug candidates.
Biotherapeutics are an integral part of modern medicine, particularly in the oncology space, due to their efficacious properties and ability to target specific molecules within the human body. The Antibody Drug Conjugate (ADC) field is a key area within the protein and antibody engineering industry. ADCs are complex molecules composed of an antibody linked to a biological active cytotoxic (anti-cancer) drug. A stable link between the antibody and cytotoxic agent is a crucial aspect of an ADC. Glythera’s highly specific, stable linker technology addresses many of the instability issues faced by current conjugation methods. Our technology platforms enable efficient and cost effective development and manufacture of new efficacious biologics that improve half-life and optimize bio-availability and which are highly specific, stable, robust and safe.
Glythera’s PermaLink® technology is a controlled, stable conjugation platform composed of a portfolio of linker designs. PermaLink™ can be employed for the selective and stable functionalization and conjugation of various cargos to proteins and peptides.
PermaCarb® is a highly stable sialic acid derivative which can be conjugated to a glycan of choice via an enzyme mediated reaction during downstream processing in a scalable and compliant fashion. Our stable glycan technology PermaCarb® is designed to facilitate the creation of biotherapeutics which can be administered at lower doses and/or reduced frequency